Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$522.5M
66M shares
52-week range
$3.86 – $9.31
74% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
1.6
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
www.evolus.comNo one on the platform currently holds EOLS.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 339,025 | $1.4M |
No one on the platform has traded EOLS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 11.6% | 39.4% | ||||
| Profit Margin % | -17.4% | -32.8% | ||||
| Free Cash Flow Margin % | -17.1% | -27.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $334M | +12.8% | $-0.03 | $-0.04–$-0.03 | — | 4 |
| 2027 | $391M | +17.1% | $0.25 | $0.22–$0.27 | 31.8× | 4 |
| 2028 | $462M | +18.0% | $0.60 | $-0.38–$1.14 | 13.3× | 6 |
| 2029 | $537M | +16.3% | $1.07 | $1.03–$1.10 | 7.4× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.03 | $0.01 | +122.3% |
| 2026-05-04 | $-0.14 | $-0.10 | +28.6% |
| 2026-03-03 | $0.06 | $0.04 | -26.3% |
| 2025-11-05 | $-0.19 | $-0.14 | +26.3% |
| 2025-08-05 | $-0.09 | $-0.24 | -166.7% |
| 2025-05-07 | $-0.10 | $-0.18 | -80.0% |
| 2025-03-04 | $0.02 | $0.01 | -50.0% |
| 2024-11-06 | $-0.08 |
| $-0.19 |
| -137.5% |
| $597M |
| — |
| KMDAKamada Ltd. | $8.09 | -2.65% | $467M | — |
| NGNENeurogene Inc. | $33.69 | -4.32% | $532M | — |
Source: Financial Modeling Prep · peers by sector/industry
$EOLS This one turned up on Equibles. Evolus, Inc. director MOATAZEDI DAVID reported selling 105,108 EOLS shares on September 2, 2026, worth about $950 thousand, in a non-derivative Form 4.
View on StockTwits ↗
$EOLS Double digits soon; the trend is your friend; don't swim against the tide.
View on StockTwits ↗$EOLS Just went positive today; feeling good about earnings estimates revisions.
View on StockTwits ↗
$EOLS Started a 500 share position at $8.15; this is primed to run.
View on StockTwits ↗
$EOLS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 up 55.56% YoY • Reported revenue of $84.08M up 21.18% YoY • Evolus raised full-year 2026 net revenue guidance to between $330 million and $337 million, adjusted gross profit margin to between 67.0% and 67.5%, and narrowed non-GAAP operating expense guidance to $212-$216 million.
View on StockTwits ↗
$EOLS reports after the close, Estimize Consensus -0 EPS and +0.68M Revs compared to WS http://www.estimize.com/eols/fq2-2026?utm_content=p
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.